[go: up one dir, main page]

NO20063650L - 4-aryl-piperidiner - Google Patents

4-aryl-piperidiner

Info

Publication number
NO20063650L
NO20063650L NO20063650A NO20063650A NO20063650L NO 20063650 L NO20063650 L NO 20063650L NO 20063650 A NO20063650 A NO 20063650A NO 20063650 A NO20063650 A NO 20063650A NO 20063650 L NO20063650 L NO 20063650L
Authority
NO
Norway
Prior art keywords
subject
compound
provides
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
NO20063650A
Other languages
English (en)
Inventor
John M Wetzel
John E Deleon
Yu Jiang
Mohammed R Marzabadi
Chen-An Chen
Kai Lu
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20063650L publication Critical patent/NO20063650L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelse er rettet mot 4-aryl-piperidiner og beslektede heterocykliske forbindelser som er selektive antagonister for melanin-konsentrerende hormon-1 (MCHl)-reseptorer. Oppfinnelsen tilveiebringer en farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av forbindelsen ifølge oppfinnelsen og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer en farmasøytisk sammensetning lagete ved å kombinere en terapeutisk effektiv mengde av forbindelsen ifølge denne oppfinnelse og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer ytterligere en fremgangsmåte for å lage en farmasøytisk sammensetning omfattende å kombinere en terapeutisk effektiv mengde av forbindelsen ifølge oppfinnelsen og en farmasøytisk akseptabel bærer. Denne oppfinnelse tilveiebringer også en fremgangsmåte for å redusere kroppsmassen til et individ hvilken omfatter å administrere til individet en mengde av en forbindelse ifølge oppfinnelsen effektiv for å redusere individets kroppsmasse. Denne oppfinnelse tilveiebringer ytterligere en fremgangsmåte for behandling av et individ som lider av depresjon og/eller angst hvilken omfatter å administrere til individet en mengde av en forbindelse ifølge oppfinnelsen effektiv for å behandle individets depresjon og/eller angst.
NO20063650A 2004-01-14 2006-08-11 4-aryl-piperidiner NO20063650L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/757,962 US20050154020A1 (en) 2004-01-14 2004-01-14 4-Aryl piperidines
PCT/US2005/001131 WO2005069834A2 (en) 2004-01-14 2005-01-13 4-aryl piperidines

Publications (1)

Publication Number Publication Date
NO20063650L true NO20063650L (no) 2006-08-11

Family

ID=34740114

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063650A NO20063650L (no) 2004-01-14 2006-08-11 4-aryl-piperidiner

Country Status (15)

Country Link
US (1) US20050154020A1 (no)
EP (1) EP1708704A4 (no)
JP (1) JP2007517906A (no)
KR (1) KR20060125825A (no)
CN (1) CN1909904A (no)
AR (1) AR047087A1 (no)
AU (1) AU2005206873A1 (no)
BR (1) BRPI0506814A (no)
CA (1) CA2552362A1 (no)
EA (1) EA011029B1 (no)
IL (1) IL176791A0 (no)
MX (1) MXPA06007660A (no)
NO (1) NO20063650L (no)
UA (1) UA85575C2 (no)
WO (1) WO2005069834A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154022A1 (en) * 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US20090048258A1 (en) * 2005-02-01 2009-02-19 Masaki Ogino Amide Compound
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
GB201419976D0 (en) 2014-11-10 2014-12-24 Univ Newcastle Biomarkers for disease progression in melanoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5382583A (en) * 1989-04-22 1995-01-17 John Wyeth & Brother, Limited Piperazine derivatives
US6326381B1 (en) * 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
UA77536C2 (en) * 2002-07-03 2006-12-15 Lundbeck & Co As H Secondary aminoaniline piperidines as mch1 antagonists and their use

Also Published As

Publication number Publication date
UA85575C2 (en) 2009-02-10
EA200601315A1 (ru) 2006-12-29
WO2005069834A3 (en) 2006-04-27
JP2007517906A (ja) 2007-07-05
WO2005069834A2 (en) 2005-08-04
MXPA06007660A (es) 2006-09-04
EP1708704A2 (en) 2006-10-11
CN1909904A (zh) 2007-02-07
CA2552362A1 (en) 2005-08-04
IL176791A0 (en) 2006-10-31
EP1708704A4 (en) 2009-08-05
AR047087A1 (es) 2006-01-04
US20050154020A1 (en) 2005-07-14
AU2005206873A1 (en) 2005-08-04
KR20060125825A (ko) 2006-12-06
BRPI0506814A (pt) 2007-06-05
EA011029B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
ATE421504T1 (de) Spirozyklische piperidine als mch1-antagonisten und ihre verwendungen
NO20053838L (no) Substituerte alkyl-amido-piperidiner
FI109121B (fi) Menetelmä terapeuttisesti aktiivisten 5-(1-hydroksi-2-piperidinopropyyli)-2-(1H,3H)-indolonianalogien valmistamiseksi
JP4597386B2 (ja) ５−ｈｔ６親和性を有するピペリジン−インドール化合物
NO319772B1 (no) Ligander med hoy affinitet for nociceptinreseptor ORL-1, farmasoytiske preparater inneholdende disse og anvendelse av dem for fremstilling av farmasoytiske preparater.
NO20063650L (no) 4-aryl-piperidiner
JP4489940B2 (ja) 化学的シナプス伝達制御において有用な複素環エーテルおよびチオエーテル化合物
TW201024268A (en) Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
TW201016700A (en) Bicyclic heterocycle derivatives and methods of use thereof
JP2003530426A (ja) Ｐｇｄ２受容体拮抗薬を用いるアレルギー状態の治療のための方法および組成物
BG64196B1 (bg) 3-пиридил енантиомери и използването им като аналгетици
WO2011119559A1 (en) Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
NO20050113L (no) Sekundaere amino-aniliniske piperidiner som MCH1-antagonister og anvendelser derav
CA2900028C (en) Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
KR101359852B1 (ko) 오렉신 길항제로서 피롤리딘-3-일메틸-아민
BRPI0409302A (pt) derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
NO20080411L (no) Alkylsulfonamiddderivater
WO2004080411A3 (en) Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
JP2006526021A (ja) 肥満およびｃｎｓ障害を治療する選択的ｄ１／ｄ５レセプタアンタゴニストとしての５ｈ−ベンゾ［ｄ］ナフト［２，１−ｂ］アゼピン誘導体
US20040157822A1 (en) Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1
JP2006526021A5 (no)
Masuko et al. Design and synthesis of a novel water-soluble NMDA receptor antagonist with a 1, 4, 7, 10-tetraazacyclododecane group
WO2006041636A3 (en) Amino substituted aryloxybenzylpiperidine derivatives
US6656958B2 (en) Substituted pyridine compounds useful for controlling chemical synaptic transmission
WO2006041635A8 (en) Arylthiobenzylpiperidine derivatives

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application